Brief: Hua Medicine Says IND Application Accepted By U.S. FDA
21/12/2023 08:24
Dec 21 (Reuters) - Hua Medicine 2552.HK :
* IND APPLICATION OF 2ND GENERATION GLUCOKINASE ALLOSTERIC
ACTIVATOR FILED WITH AND ACCEPTED BY U.S. FDA
Further company coverage: 2552.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hua Medicine
See all newsBrief: Hua Medicine Expects Loss Of RMB30.2 Mln For HY
Brief: Hua Medicine Posts Profit For The Year RMB1.11 Billion
Brief: Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR
Brief: Hua Medicine Posts H1 Revenue Of RMB 217.4 Million
Brief: Hua Medicine Expects RMB1,184.1 Million Profit For HY